Eli Lilly's board announced a $1.73 dividend per share for the second quarter of 2026, payable on June 10 to shareholders recorded by May 15. This dividend reflects the company's ongoing commitment to returning value to shareholders amid its continued advancements in biotechnology and medicine. Investors can expect this payout as part of Lilly's strategy to support its growth and innovation in treating major health challenges globally.
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
The Frost & Sullivan Institute has recognized 50 leading companies with the 2026 Visionary Growth Leadership Best Practices Recognition for embedding innovation, measurable impact, and sustainability into their growth strategies. These companies, inc...
Eli Lilly announced positive Phase 1 results for AJ1-11095, a novel type II JAK2 inhibitor targeting myelofibrosis patients who failed type I JAK2 inhibitors. The drug demonstrated a strong safety profile, significant spleen size reduction, symptom i...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
